John Fromson

John Fromson has more than 35 years experience as a scientist, manager and entrepreneur in the healthcare and chemistry fields.
He worked for 18 years at ICI Pharmaceuticals and Hoechst and, in particular, as Research Director for Hoechst Pharmaceuticals in charge of developing three major products.
He subsequently spent 5 years at Hazleton, a contract services organisation in the pharmaceutical industry.
In 1992, he became Vice-President of Clinical Development at Vanguard Medica, where he played a key role in the company’s IPO and the development of the anti-migraine drug, frovatriptan.
In 1998, he founded Devco Pharmaceuticals, a company developing neurology therapeutics.
In 2002, he became Executive Chairman of Ultrafine, a company specialised in providing chemistry services to the pharmaceutical industry.
During this period he carried out a major, successful restructuring operation which led to the sale of the company to Sigma Aldrich within two years.
In 2006, he became a shareholder and Executive Chairman of Dextra Laboratories, a company manufacturing chemistry products for the pharmaceutical industry.
In 2007, following the successful completion of a restructuring programme and a significant increase in annual revenues, the company was sold to Summit Group plc, listed on AIM.
Mr. Fromson has a BSc degree in Chemistry, and a PhD from Queen’s University (Belfast).